Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Joseph M. Antonello"'
Autor:
Gowrisankar Rajam, Yuhua Zhang, Joseph M. Antonello, Rebecca J. Grant-Klein, Lauren Cook, Reshma Panemangalore, Huy Pham, Stephanie Cooper, Thomas D. Steinmetz, Jennifer Nguyen, Mathias W. Pletz, Grit Barten-Neiner, Rocio D. Murphy, Leonard J. Rubinstein, Katrina M. Nolan
Publikováno v:
mSphere, Vol 7, Iss 4 (2022)
ABSTRACT Streptococcus pneumoniae is a major cause of community-acquired pneumonia (CAP) in young children, older adults, and those with immunocompromised status. Since the introduction of pneumococcal vaccines, the burden of invasive pneumococcal di
Externí odkaz:
https://doaj.org/article/54c92dbec88d43e1b1ac8f0c54ada833
Publikováno v:
Am J Trop Med Hyg
Gamma irradiation (GI) is included in the CDC guidance on inactivation procedures to render a group of select agents and toxins nonviable. The Ebola virus falls within this group because it potentially poses a severe threat to public health and safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2e593bc150d1a68a182df6d5996e4e6
https://doi.org/10.4269/ajtmh.20-1055
https://doi.org/10.4269/ajtmh.20-1055
Autor:
Joseph M. Antonello, Rebecca Greway, Tina Green, Polly De Gorguette D'Argoeuves, Adrienne H Howlett, Yuhua Zhang, Cyrille J Bonhomme, Katrina M. Nolan, Rocio D Murphy, David Goldblatt
Publikováno v:
Bioanalysis. 12:1363-1375
Aim: To re-optimize the pneumococcal (Pn) electrochemiluminescence (ECL) assay and to validate and bridge the enhanced assay to the WHO ELISA, to support the Phase III clinical trial program for V114, a 15-valent Pn conjugate vaccine. Materials & met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eee427d50cc414a25552a53a65f37b5c
https://doi.org/10.4155/bio-2020-0023
https://doi.org/10.4155/bio-2020-0023
Autor:
Rebecca J. Grant-Klein, Sheri Dubey, Stephen B. Kennedy, Jakub K. Simon, Rick Nichols, Joseph M. Antonello
Publikováno v:
Vaccine. 38:4885-4891
The recombinant vesicular stomatitis virus - Zaire Ebola virus envelope glycoprotein (rVSVΔG-ZEBOV-GP) vaccine is a live recombinant vesicular stomatitis virus (VSV) where the VSV G protein is replaced with ZEBOV-GP. To better understand the immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::022a9148d37e14de14028377cfe85234
https://doi.org/10.1016/j.vaccine.2020.04.061
https://doi.org/10.1016/j.vaccine.2020.04.061
Autor:
Amy S. Espeseth, Robin M. Kaufhold, Joseph M. Antonello, Julie M. Skinner, Melissa A. Boddicker, Jodie A. Field, Bob J. Lucas, Jon H. Heinrichs, Jeffrey G. Smith
Publikováno v:
World Journal of Vaccines. :49-69
Identifying relevant animal challenge models adds to the complexity of human vaccine development. Murine challenge models have been the most utilized animal model for Chlamydia trachomatis vaccine development. The question arises as to whether the C.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1643b9bca8ad975bd0e314132ae9b8a
https://doi.org/10.4236/wjv.2019.92004
https://doi.org/10.4236/wjv.2019.92004
Autor:
Leonard J. Rubinstein, Kevin B. Gurney, Sarah Daijogo, Joseph M. Antonello, Bogardus Leah A, Giacone Danila G, Dengyun Sun, Melissa C. Whiteman
Publikováno v:
The American Journal of Tropical Medicine and Hygiene
Vaccine immunogenicity and clinical efficacy are often assessed by the measure of serum-neutralizing antibodies. The present gold standard for detecting neutralizing antibodies against many viruses, including dengue, is the plaque/focus reduction neu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e153843fa96dd04176b3b264eb39194
https://doi.org/10.4269/ajtmh.17-0948
https://doi.org/10.4269/ajtmh.17-0948
Autor:
Katrina M. Nolan, Tina Green, Rocio D Murphy, Marie E Bonhomme, Joseph M. Antonello, Christina J Schier
Publikováno v:
Bioanalysis. 12(14)
Background: To streamline and improve throughput, the agar-based multiplexed opsonophagocytic killing assay (MOPA) was optimized and validated on a microcolony platform for use in the Phase III clinical trial program for V114, an MSD 15-valent pneumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c96c5336bd635b3fa46c08a2fe077285
https://pubmed.ncbi.nlm.nih.gov/32686954
https://pubmed.ncbi.nlm.nih.gov/32686954
Autor:
Andrew J. Bett, Dai Wang, Zhiyun Wen, Andrew H. Latham, Lan Zhang, Kalpit A. Vora, Michael P. Citron, Jeffrey S. Smith, Marian E. Gindy, Christine A. Shaw, Joseph M. Antonello, Jessica A. Flynn, Ryan Swoyer, Cheryl Callahan, Giuseppe Ciaramella, Paloma Cejas, Daniel J. DiStefano, Kapil Bahl, Daniel C. Freed, Kara S. Cox, Gregory O’ Donnell, Amy S. Espeseth, Sinoeun Touch, Jennifer D. Galli, Daria J. Hazuda
Publikováno v:
NPJ Vaccines
npj Vaccines, Vol 5, Iss 1, Pp 1-14 (2020)
npj Vaccines, Vol 5, Iss 1, Pp 1-14 (2020)
The RSV Fusion (F) protein is a target for neutralizing antibody responses and is a focus for vaccine discovery; however, the process of RSV entry requires F to adopt a metastable prefusion form and transition to a more stable postfusion form, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f124a59770591309d57e7f3b9697da6
http://europepmc.org/articles/PMC7021756
http://europepmc.org/articles/PMC7021756
Autor:
Shara Dellatore, Bogardus Leah A, Dengyun Sun, Leonard J. Rubinstein, Kevin B. Gurney, Amy Hsu, Melissa C. Whiteman, Joseph M. Antonello
Publikováno v:
Journal of Immunological Methods. 494:113054
Respiratory syncytial virus (RSV) is a common pathogen causing severe respiratory illness in infants and elder adults. The development of an effective RSV vaccine is an important unmet medical need and an area of active research. The traditional meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e1cb83a6fc4a7893b176516c14f7ae9
https://doi.org/10.1016/j.jim.2021.113054
https://doi.org/10.1016/j.jim.2021.113054
Autor:
Dominique Wauters, Ki-Hyun Kim, David Goldblatt, G. L. Xie, Robert L. Burton, David A. Cooper, Moon H. Nahm, Mustafa Akkoyunlu, F. Williams, Lucy Roalfe, Brian D. Plikaytis, Joseph M. Antonello
Publikováno v:
Clinical and Vaccine Immunology. 24
Opsonophagocytic assays (OPAs) are routinely used for assessing the immunogenicity of pneumococcal vaccines, with OPA data often being utilized for licensure of new vaccine formulations. However, no reference serum for pneumococcal OPAs is available,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ca25db66daa569c3d01c41282093625
https://doi.org/10.1128/cvi.00457-16
https://doi.org/10.1128/cvi.00457-16